Fondazione IRCCS Istituto Nazionale dei Tumori, Milano: Carcinoma trials

The registry lists 25 Carcinoma studies with Fondazione IRCCS Istituto Nazionale dei Tumori, Milano as lead sponsor. 6 are open to participants now and 0 have results posted.

Phase 2 17Phase 3 1No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 StudyRecruitingNCT07030569
• Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyRecruitingNCT06805812
• Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder CancerNot yet recruitingNCT06528483Phase 2
• Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)Not yet recruitingNCT06086288Phase 2
• The ImmunoXXL StudyRecruitingNCT05879328
• Quantifying Systemic Immunosuppression to Personalize Cancer TherapyRecruitingNCT05621837
• Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)Status unknownNCT05372302
• Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)Status unknownNCT04891055
• Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIbCompletedNCT04462445Phase 2
• Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)Status unknownNCT03943602Phase 2
• hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"Status unknownNCT03824691Phase 2
• Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial CarcinomaCompletedNCT03464734Phase 2
• A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinomaCompletedNCT03463681Phase 2
• Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)Status unknownNCT03449173Phase 2
• caBozantinib in cOllectiNg ductS Renal Cell cArcInomaCompletedNCT03354884Phase 2
• Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the BreastCompletedNCT03002766Phase 2
• Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14CompletedNCT02860936Phase 2
• Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder CarcinomaCompletedNCT02736266Phase 2
• Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers DiscoveryTerminatedNCT02535351Phase 3
• Second Line Sorafenib After Pazopanib in Patients With RCCTerminatedNCT02122003Phase 2
• Alisertib in Chemotherapy-pretreated Urothelial CancerCompletedNCT02109328Phase 2
• Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the PenisCompletedNCT01728233Phase 2
• Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the MetastasesStatus unknownNCT01444807Phase 2
• Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through DownstagingCompletedNCT01387503Not applicable
• Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular CarcinomaCompletedNCT00910572Phase 2